Login to Your Account

CoTherix Gets Approval For Inhaled PAH Drug Ventavis

By Karen Pihl-Carey

Tuesday, January 4, 2005
Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for Ventavis, an inhaled product in-licensed from Schering AG in October 2003. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription